Xiaoli Huang, Sanbin Wang, Lin Liu, L. Luo, Zhongtao Yuan
{"title":"Janus激酶1/2抑制剂ruxolitinib防治移植物抗宿主病的研究进展","authors":"Xiaoli Huang, Sanbin Wang, Lin Liu, L. Luo, Zhongtao Yuan","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.010","DOIUrl":null,"url":null,"abstract":"Graft versus host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is one of the leading causes of death in patients after allo-HSCT. Currently, the classic GVHD prevention regimens are calcineurin inhibitor represented by cyclosporine and tacrolimus in combination with methotrexate or mycophenolate mofetil.The first-line standard regimen for GVHD is based on glucocorticoids. However, this regimen is only effective for some patients, and with a long course of treatment and many adverse reactions, and the patients are easy to be infected. Recent researches show that Janus kinase (JAK) 1/2 inhibitor ruxolitinib has evident clinic efficacy in preventing and treating GVHD with rapid initial effect and less adverse reactions. This article summarizes the basic and clinical researches about ruxolitinib in preventing and treating GVHD, and aims to explore new regimens for preventing and treating GVHD. \n \n \nKey words: \nGraft vs host disease; Janus kinases; Janus kinase 1; Janus kinase 2; Hematopoietic stem cell transplantation; Adverse effects; Ruxolitinib","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"233-237"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress of Janus kinase 1/2 inhibitor ruxolitinib in preventing and treating graft versus host disease\",\"authors\":\"Xiaoli Huang, Sanbin Wang, Lin Liu, L. Luo, Zhongtao Yuan\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.03.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Graft versus host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is one of the leading causes of death in patients after allo-HSCT. Currently, the classic GVHD prevention regimens are calcineurin inhibitor represented by cyclosporine and tacrolimus in combination with methotrexate or mycophenolate mofetil.The first-line standard regimen for GVHD is based on glucocorticoids. However, this regimen is only effective for some patients, and with a long course of treatment and many adverse reactions, and the patients are easy to be infected. Recent researches show that Janus kinase (JAK) 1/2 inhibitor ruxolitinib has evident clinic efficacy in preventing and treating GVHD with rapid initial effect and less adverse reactions. This article summarizes the basic and clinical researches about ruxolitinib in preventing and treating GVHD, and aims to explore new regimens for preventing and treating GVHD. \\n \\n \\nKey words: \\nGraft vs host disease; Janus kinases; Janus kinase 1; Janus kinase 2; Hematopoietic stem cell transplantation; Adverse effects; Ruxolitinib\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"233-237\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Research progress of Janus kinase 1/2 inhibitor ruxolitinib in preventing and treating graft versus host disease
Graft versus host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is one of the leading causes of death in patients after allo-HSCT. Currently, the classic GVHD prevention regimens are calcineurin inhibitor represented by cyclosporine and tacrolimus in combination with methotrexate or mycophenolate mofetil.The first-line standard regimen for GVHD is based on glucocorticoids. However, this regimen is only effective for some patients, and with a long course of treatment and many adverse reactions, and the patients are easy to be infected. Recent researches show that Janus kinase (JAK) 1/2 inhibitor ruxolitinib has evident clinic efficacy in preventing and treating GVHD with rapid initial effect and less adverse reactions. This article summarizes the basic and clinical researches about ruxolitinib in preventing and treating GVHD, and aims to explore new regimens for preventing and treating GVHD.
Key words:
Graft vs host disease; Janus kinases; Janus kinase 1; Janus kinase 2; Hematopoietic stem cell transplantation; Adverse effects; Ruxolitinib
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
